PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health.
The main questions PLATIPUS aims to answer are:
1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains)
2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains).
This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.

Start Date01 Nov 2025

Sponsor / Collaborator

University of Melbourne

[+10]

NCT06972849

/ Not yet recruitingNot ApplicableIIT

BabyCCINO: Caffeine Citrate to Improve Neonatal Outcomes. A Neonatal Domain Within PLATIPUS.

The goal of this clinical trial to learn what dose/s of caffeine citrate works to treat preterm born babies who have episodes where they stop breathing. It will also learn about the safety of different doses of caffeine citrate for the variety of preterm-born babies that are prescribed this.
The main question it aims to answer is: Which dose is the optimal dose of caffeine citrate for very preterm babies to prevent short-term death and disease?
Researchers will compare three different doses of caffeine citrate, which are already used in clinical practice to treat breathing stoppages in preterm babies, to see which dose works best. No placebo will be used.
Participants will be given a 'loading' dose of caffeine citrate <72 hours of life, and a smaller 'maintenance' dose once a day, for as long as the baby needs this.
This trial will be undertaken as part of the PLATIPUS trial (NCT06461429).

Start Date01 Oct 2025

Sponsor / Collaborator

University of Melbourne

NCT06518603

/ Not yet recruitingPhase 4IIT

Randomized Controlled Trial of Caffeine Citrate in Preterm Infants at Risk of Apnea in Zambia

The goal of this clinical trial is to learn if caffeine citrate prevents apneic events that result in sick visits in moderately preterm infants after discharge from the hospital. It will also learn if the use of caffeine leads to better developmental outcomes at 12 months of age.
Our research questions are:
1. Does continued treatment of moderately preterm newborns with caffeine citrate after hospital discharge prevent or decrease apneic events that result in sick visits?
2. Will the continued use of caffeine citrate lead to improved developmental outcomes among infants at 12 months of age?
Researchers will compare caffeine citrate to a placebo (a look-alike substance that contains no drug) to see if caffeine citrate prevents apneic spells which result in healthcare visits.
Parents of participants will:
1. Administer caffeine citrate 20mg/kg/day or a placebo (equivalent volume of sterile water) orally every day for up to 28 days after hospital discharge
2. Keep a diary of symptoms and any apneic events
3. Check in with researchers via telephone call once a week
4. Return to clinic for infant physical examination at 28 days
5. Return to the clinic for infant physical examination at 2 months
5. Return to clinic for infant neurodevelopmental examination with Ages and Stages Questionnaire at 12 months of age

Start Date01 Sep 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

100 Clinical Results associated with Caffeine Citrate

100 Translational Medicine associated with Caffeine Citrate

100 Patents (Medical) associated with Caffeine Citrate

45,016

Literatures (Medical) associated with Caffeine Citrate

31 Dec 2025·Journal of the International Society of Sports Nutrition

Caffeine supplementation improved movement patterns and reactive agility in rugby sevens matches in male collegiate players

Article

Author: Hsueh, Chang-Li ; Sun, Cheng-Yen ; Chang, Chen-Kang

PURPOSE:

Rugby sevens is a high-intensity contact sport often played in two-day tournaments. Caffeine is widely used by rugby players for its performance-enhancing effects. This study aimed to investigate the impact of caffeine supplementation on various performance metrics, including distance covered at different speeds, acceleration, deceleration, collisions, and repeated high-intensity efforts across four matches over two consecutive days in collegiate male rugby sevens players. Reactive agility, a key performance attribute in rugby sevens, was also assessed before each match.

METHODS:

A position-matched, double-blind, randomized crossover design was employed, with six male collegiate rugby players (mean height: 1.78 ± 0.09 m, mean weight: 81.3 ± 9.2 kg, mean age: 21.5 ± 0.8 years) participating in two trials. Each trial consisted of a two-day tournament, with two matches per day. Performance was monitored using global positioning system units to track distance covered in various speed zones, as well as total distance, frequency of acceleration, deceleration, collisions, and repeated high-intensity efforts.

RESULTS:

The results indicated that in the placebo trial, participants covered significantly more distance at a walking pace (0-6 km/h) in match 4 compared to match 3 (match 3: 480.3 ± 32.7 m; match 4: 629.4 ± 21.3 m, p < 0.001, d = 0.117). In the caffeine trial, players covered significantly more distance at a jogging pace (6-12 km/h) in match 4 compared to the placebo trial (caffeine: 405.9 ± 9.8 m; placebo: 303.6 ± 20.2 m, p = 0.015, d = 1.693). Reactive agility was significantly better in the caffeine trial before match 3 (caffeine trial: 1.80 ± 0.17 s; placebo trial: 2.07 ± 0.18 s, p = 0.038, d = 0.858).

CONCLUSIONS:

Caffeine supplementation at 3 mg/kg may increase jogging and reduce walking and standing in the final match of a two-day rugby sevens tournament, while also improving reactive agility on the second day. This suggests that by mitigating fatigue in the later stages of the tournament, caffeine allowed players to shift from low-intensity activities to higher-intensity efforts. These adjustments may improve both offensive and defensive performance during rugby sevens matches. Therefore, rugby sevens players could benefit from taking caffeine supplements in the later stages of 2-day tournaments to optimize their performance.

31 Dec 2025·Journal of the International Society of Sports Nutrition

Effects of different dietary supplements on athletic performance in soccer players: a systematic review and network meta-analysis

Review

Author: Zhu, Xiaolin ; Nasharuddin, Nurul Amelina ; Xiang, Changqing ; Tengku Kamalden, Tengku Fadilah ; Luo, Hua

BACKGROUND:

As dietary supplements play a crucial role in meeting the unique nutritional needs of soccer players, a growing body of studies are exploring the effects of dietary supplements on athletic performance in soccer players. The effectiveness of certain supplements, such as caffeine and creatine, remains debated due to inconsistent results across studies. Therefore, this systematic review and Bayesian network meta-analysis was conducted to tentatively identify the most effective dietary supplements for soccer players.

METHODS:

We searched PubMed, Web of Science, Cochrane, Embase, and SPORTDiscus from database establishment to 5 February 2024 to identify randomized controlled trials (RCTs) evaluating the effects of different dietary supplements on athletic performance in soccer players. The risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials. A Bayesian network meta-analysis was performed using the R software and Stata 18.0. A subgroup analysis was conducted based on the competitive level of the athletes.

RESULTS:

Eighty RCTs were included, with 1,425 soccer players randomly receiving 31 different dietary supplements or placebo. The network meta-analysis showed that compared with placebo, carbohydrate + protein (SMD: 2.2, very large), carbohydrate + electrolyte (SMD: 1.3, large), bovine colostrum (SMD: moderate) and caffeine (SMD: 0.29, small) were associated with a significant effect on increasing the distance covered. Kaempferia parviflora (SMD: 0.46, small) was associated with a significant effect on enhancing muscular strength. Beta-alanine (SMD: 0.83, moderate), melatonin (SMD: 0.75, moderate), caffeine (SMD: 0.37, small), and creatine (SMD: 0.33, small) were associated with a significant effect on enhancing jump height. Magnesium creatine chelate (SMD: -3.0, very large), melatonin (SMD: -1.9, large), creatine + sodium bicarbonate (SMD: -1.4, large), and arginine (SMD: -1.2, moderate) were associated with a significant effect on decreasing sprint time. Creatine + sodium bicarbonate (SMD: -2.3, very large) and caffeine (SMD: -0.38, small) were associated with a significant effect on improving agility. Sodium pyruvate (SMD: 0.50, small) was associated with a significant effect on increasing peak power. Magnesium creatine chelate (SMD: 1.3, large) and sodium pyruvate (SMD: 0.56, small) were associated with a significant effect on increasing mean power. Carbohydrate + electrolyte (SMD: -0.56, small) was associated with a significant effect on improving the rating of perceived exertion.

CONCLUSIONS:

This study suggests that a range of dietary supplements, including caffeine, creatine, creatine + sodium bicarbonate, magnesium creatine chelate, carbohydrate + electrolyte, carbohydrate + protein, arginine, beta-alanine, bovine colostrum, Kaempferia parviflora, melatonin, and sodium pyruvate, can improve athletic performance in soccer players. This review provides evidence-based guidance for soccer coaches and nutritionists on using dietary supplements to enhance specific performance measures.

31 Dec 2025·Journal of the International Society of Sports Nutrition

Acute effects of isolated and combined dietary nitrate and caffeine ingestion on ergometer-based 1000 m time trial performance in highly trained kayakers

Article

Author: Bruhn, Sven ; Weippert, Matthias ; Mittlmeier, Thomas ; Behrens, Martin ; Pollex, Johannes

BACKGROUND:

Dietary nitrate (BR) and caffeine (CAF) ingestion have been shown to increase sports performance. However, the isolated and combined effects of BR and CAF ingestion on time trial (TT) performance as well as the accompanying physiological and perceptual responses have never been investigated in highly trained kayak athletes. Therefore, the present study examined the impact of an isolated and combined supplementation with BR (140 ml beetroot concentrate, ~12.5 mmol nitrate) and CAF (3 mg/kg bodyweight) on 1000 m ergometer TT performance as well as the accompanying physiological (i.e. cardiorespiratory function, muscle oxygenation, muscle activity) and perceptual responses (i.e. fatigue, effort, and exercise-induced pain perception) in male highly trained kayakers. It was hypothesized that the isolated ingestion of BR and CAF would both improve ergometer-based 1000 m TT performance and induce supplement-specific physiological and perceptual responses. Considering the primary effects of BR on muscle function and of CAF on the central nervous system, it was further assumed that the combined ingestion will result in an additional performance increase and supplement-specific physiological and perceptual responses.

METHODS:

Using a prospective, randomized, controlled, double-blind crossover design, 12 male highly trained kayak athletes from local clubs were investigated. They completed four measurement sessions resulting in four randomized conditions: (i) BR+CAF; (ii) BR+CAF placebo (BR+PLA); (iii) CAF+BR placebo (CAF+PLA); and (iv) BR placebo + CAF placebo (PLA+PLA). An air-braked instrumented kayak-ergometer was used to record 1000 m TT performance, power output, and stroke frequency. Heart rate (HR), oxygen uptake (VO₂), maximum VO₂ (VO_2max), respiratory equivalent of O₂ (VE/VO₂), and carbon dioxide (VE/VCO₂) were measured continuously. Furthermore, oxygenation of the deltoid muscle was measured with near-infrared spectroscopy (mNIRS) and muscle activity of nine unilateral muscles with surface electromyography (i.e. deltoideus, serratus anterior, triceps brachii caput lateralis, trapezius, infraspinatus, latissimus dorsi, obliquus externus, flexor carpi radialis, and vastus lateralis muscle) during the 1000 m TT. After the TT, fatigue, effort, and exercise-induced pain perception were queried. One- and two-way analysis of variance with repeated measures were conducted to determine differences between conditions for the entire 1000 m TT and predefined sections (0-50 m, 50-100 m, 100-150 m, 150-250 m, 250-500 m, 500-750 m, 750-1000 m), respectively (p ≤ 0.05).

RESULTS:

The supplements did not have an ergogenic effect on TT performance compared to the PLA+PLA condition, either in isolation or in combination. The same applied to the majority of physiological parameters and the perceptual responses. Nevertheless, VE/VO₂ was lower during the sections 150-250 m (-5.00%; p = 0.02) and 250-500 m (-3.49%; p = 0.03) in the BR+PLA condition, whereby VE/VCO₂ was higher during the section 150-250 m (4.19%; p = 0.04) in the CAF+PLA compared to the PLA+PLA condition, respectively.

CONCLUSIONS:

Data indicate that the isolated and combined ingestion of BR and CAF had no effect on 1000 m TT performance, the majority of physiological responses, and perceptual responses in highly trained kayakers. These findings might be related to the dosage and/or a ceiling effect due to the already efficient vascular, metabolic, and muscle function, including high amounts of endogenous produced nitric oxide, in athletes.

135

News (Medical) associated with Caffeine Citrate

29 May 2025

·www.sciencedaily.com

How does coffee affect a sleeping brain?

Coffee can help you stay awake. But what does caffeine actually do to your brain once you're asleep? Using AI, a team of researchers has an answer: it affects the brain's 'criticality'. Caffeine is not only found in coffee, but also in tea, chocolate, energy drinks and many soft drinks, making it one of the most widely consumed psychoactive substances in the world. In a study published in April in Nature Communications Biology, a team of researchers from Université de Montréal shed new light on how caffeine can modify sleep and influence the brain's recovery -- both physical and cognitive -- overnight. The research was led by Philipp Thölke, a research trainee at UdeM's Cognitive and Computational Neuroscience Laboratory (CoCo Lab), and co-led by the lab's director Karim Jerbi, a psychology professor and researcher at Mila -- Quebec AI Institute. Working with with sleep-and-aging psychology professor Julie Carrier and her team at UdeM's Centre for Advanced Research in Sleep Medicine, the scientists used AI and electroencephalography (EEG) to study caffeine's effect on sleep. They showed for the first time that caffeine increases the complexity of brain signals and enhances brain "criticality" during sleep. Interestingly, this was more pronounced in younger adults. "Criticality describes a state of the brain that is balanced between order and chaos," said Jerbi. "It's like an orchestra: too quiet and nothing happens, too chaotic and there's cacophony. Criticality is the happy medium where brain activity is both organized and flexible. In this state, the brain functions optimally: it can process information efficiently, adapt quickly, learn and make decisions with agility." Added Carrier: "Caffeine stimulates the brain and pushes it into a state of criticality, where it is more awake, alert and reactive While this is useful during the day for concentration, this state could interfere with rest at night: the brain would neither relax nor recover properly." 40 adults studied To study how caffeine affects the sleeping brain, Carrier's team recorded the nocturnal brain activity of 40 healthy adults using an electroencephalogram. They compared each participant's brain activity on two separate nights -- one when they consumed caffeine capsules three hours and then one hour before bedtime, and another when they took a placebo at the same times. "We used advanced statistical analysis and artificial intelligence to identify subtle changes in neuronal activity," said Thölke, the study's first author. "The results showed that caffeine increased the complexity of brain signals, reflecting more dynamic and less predictable neuronal activity, especially during the non-rapid eye movement (NREM) phase of sleep that's crucial for memory consolidation and cognitive recovery." The researchers also discovered striking changes in the brain's electrical rhythms during sleep: caffeine attenuated slower oscillations such as theta and alpha waves -- generally associated with deep, restorative sleep -- and stimulated beta wave activity, which is more common during wakefulness and mental engagement. "These changes suggest that even during sleep, the brain remains in a more activated, less restorative state under the influence of caffeine," says Jerbi, who also holds the Canada Research Chair in Computational Neuroscience and Cognitive Neuroimaging. "This change in the brain's rhythmic activity may help explain why caffeine affects the efficiency with which the brain recovers during the night, with potential consequences for memory processing." People in their 20s more affected The study also showed that the effects of caffeine on brain dynamics were significantly more pronounced in young adults between ages 20 and 27 compared to middle-aged participants aged 41 to 58, especially during REM sleep, the phase associated with dreaming. Young adults showed a greater response to caffeine, likely due to a higher density of adenosine receptors in their brains. Adenosine is a molecule that gradually accumulates in the brain throughout the day, causing a feeling of fatigue. "Adenosine receptors naturally decrease with age, reducing caffeine's ability to block them and improve brain complexity, which may partly explain the reduced effect of caffeine observed in middle-aged participants," Carrier said. And these age-related differences suggest that younger brains may be more susceptible to the stimulant effects of caffeine. Given caffeine's widespread use around the world, especially as a daily remedy for fatigue, the researchers stress the importance of understanding its complex effects on brain activity across different age groups and health conditions. They add that further research is needed to clarify how these neural changes affect cognitive health and daily functioning, and to potentially guide personalized recommendations for caffeine intake.

Clinical Result

29 May 2025

·www.sciencedaily.com

Resetting the fight-or-flight response

The activation of Protein Kinase A (PKA) is a critical part in how the body responds to stress and starvation. Using a variety of imaging and biochemical techniques, a team of researchers has revealed how the metabolic cycle that activates PKA resets itself between stressful events. Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allows the body to react swiftly to stress or starvation. Critical to this "fight-or-flight" or stress response is a molecular cycle that results in the activation of Protein Kinase A (PKA), a protein involved in everything from metabolism to memory formation. Now, a study by researchers at Penn State has revealed how this cycle resets between stressful events so the body is prepared to take on new challenges. The details of this reset mechanism, uncovered through a combination of imaging, structural and biochemical techniques, was recently published in the Journal of the American Chemical Society. "Some of the early changes in the fight-or-flight response include the release of hormones, like adrenaline from stress or glucagon from starvation," said Ganesh Anand, associate professor of chemistry and of biochemistry and molecular biology in the Penn State Eberly College of Science and lead author of the paper. "These hormones trigger an important molecular cycle that ultimately activates PKA, a versatile protein that can regulate more than a hundred different target proteins inside the cell. Better understanding of this cycle has implications not only for stress and starvation, but for other things we put in our bodies, like caffeine and certain drugs that initiate or extend the cycle." In all cells of organisms from yeast to humans, PKA oscillates between active and inactive states. When hormones like glucagon or adrenaline bind to a specific location in the cell, they generate a molecule called cyclic AMP, or cAMP. This in turn binds to the inactive complex of proteins that contains PKA, switching the PKA to a more active state. But how exactly this cycle completes and the system resets itself has remained unclear. "You don't want this cycle to be perpetually on and responding once the stressful situation has passed," Anand said. "You want to be able to reset the system. Dysregulation of PKA due to errors in this reset process can lead to cardiovascular disease, metabolic syndromes and other disorders. We wanted to know how long this system could remain active and how you can shut it off." Using multiple imaging techniques -- including electron microscopy and the higher-resolution cryo-electron microscopy as well as biochemical techniques and several different forms of mass spectrometry, which provided insights into the dynamics of the complex -- the researchers uncovered at least three conformations of the complex that occur during the reset process that were previously unknown. They also clarified the physical space that these conformations use within the cell. "Molecules are not rigid rocks; they are constantly fluctuating, almost like they are breathing," Anand said. "Cryo-electron microscopy is a powerful imaging technique that has gained a lot of traction, but it ultimately gives you a static image. If you look at a photograph of a leg, you can guess at how the knee and the ankle work, but it's just a guess. We used a variety of other techniques to really understand the mobile 'joints' of this complex. It's an iterative approach; we moved back and forth between the different techniques as we uncovered new insights so that we could really understand what the different components are doing during a variety of conformational changes." Integral to the reset mechanism are phosphodiesterase proteins, or PDE, which remove the cAMP from the PKA complex, rendering the complex inactive once again. As the cAMP is removed, it can accumulate within the cell, allowing the number of reset cycles to be tracked. "The system becomes more efficient as it goes through more cycles," said Varun Venkatakrishnan, graduate student in chemistry in the Penn State Eberly College of Science and first author of the paper. "Just like a runner can build up stamina with practice, there is some capacity for building endurance with this fight-or-flight response. This system has a built-in timer, which can record how many laps it has run. We would like to better understand the implications of activating the cycle many times in a row. It's also possible we could trick the system into thinking it has run more laps than it has by adding cAMP." The researchers said that allowing the system to reset between stressors is physiologically important. For example, cAMP encourages memory formation, allowing memories to be formed around stressful events. Long-term stress can also increase the risk of developing Type 2 diabetes and impact the functioning of a variety of systems. "In the modern world, we are continuously getting stimulated, including by substances like caffeine and drugs, and we'd like to better understand what happens when the cycle is activated for a long time," Anand said. "Caffeine is a PDE inhibitor, so it essentially pauses the reset mechanism, and we end up getting the buzz from the stress response without the actual stress. And some drugs called glucagon-like-peptides or GLPs, such as those used to alter appetite and so called 'anti-obesity' drugs, can modulate the PKA cycle. If we can find a way to keep the reset for longer, we might be able to find a way to counteract some effects of stress." Additionally, the researchers said that the integrative, procedural framework of using cryo-electron microscopy, mass spectrometry and biochemical techniques could be adapted to understand the moving parts of a wide variety of protein complexes. In addition to Anand and Venkatakrishnan, the research team at Penn State includes Tatiana Laremore, associate research professor and director of the Proteomics and Mass Spectrometry Core Facility; Theresa Buckley, graduate student in chemistry; and Jean-Paul Armache, assistant professor of biochemistry and molecular biology. Data for this paper was collected using the Proteomics and Mass Spectrometry Core Facility and the Cryo-Electron Microscopy Core Facility within the Penn State Huck Institutes of the Life Sciences. Funding from Penn State supported this research.

23 Jan 2025

·www.prnewswire.com

FUTURE OF HEALTH: CARDONE VENTURES PARTNERS WITH REVIV TO LAUNCH THE WORLD'S FIRST PRECISION NUTRITION SYSTEM IN THE UK

LONDON, Jan. 23, 2025 /PRNewswire/ -- Cardone Ventures, the business growth and investment firm led by Brandon Dawson and Grant Cardone, is proud to announce the UK launch of the world's first patented 10X Precision Nutrition System in partnership with REVIV Global, the leader in personalized health and IV therapy. This milestone event marks the first expansion of Cardone Ventures' portfolio company, 10X Health, outside the United States, setting a new global standard for personalized health solutions. With REVIV's expertise in IV therapy, boasting over 3 million therapies delivered worldwide, and 10X Health's cutting-edge genetic technology, this collaboration introduces a revolutionary way for individuals to optimize their health and well-being through their unique genetic makeup. The UK launch serves as the first step in a strategic international rollout, with plans to expand to other key markets globally. Revolutionizing Health with Unmatched Genetic Insights The 10X Precision Genetic Test combines cutting-edge technology with artificial intelligence to analyze up to 20 million genetic variations, delivering unparalleled insights into an individual's biological data with 99.97% accuracy. Developed in Austria by renowned biotechnologist Dr. Daniel Wallerstorfer, PhD, the system represents the pinnacle of precision health science. The process is simple and non-invasive: customers provide an oral swab sample, which is analyzed at a state-of-the-art laboratory using Micro Array technology to capture 700,000 DNA variations. AI-powered bioinformatics then expands the analysis to 20 million variations, delivering a detailed, actionable report within just six weeks. The comprehensive 400+ page report provides insights into nutrition, weight management, and lifestyle factors, such as: Caffeine consumption and absorption Inflammation and immune system performance Salt sensitivity and blood pressure Fat distribution and muscle preservation And much more. More information can be found on: Transforming Health and Wellness Solutions With results in hand, customers gain access to personalized health tools, including: 10X Precision Supplements: Custom-formulated, patented micro-bead supplements designed for optimal absorption and bioavailability to improve digestion, immunity, skin health, energy levels, and metabolic function. 10X Precision IV Drip Therapy: The only IV therapy designed using an individual's unique genetic profile, delivering the ultimate in tailored wellness. Clients can book their bespoke IV therapy via a QR code on their report, accessible at any REVIV or 10X Health clinic worldwide. "This partnership eradicates the guesswork of health fads and trends, replacing them with science-backed, data-driven solutions that uniquely cater to each individual," said Sarah Lomas, CEO of REVIV Global. "With more than a decade of R&D, 3 million IVs delivered, and the integration of cutting-edge genetic science, we're empowering people to take control of their health in a way that's never been possible before. This is the future of health and wellness." A Global Vision with Local Impact "This launch represents a monumental step in achieving our mission to revolutionize the health and wellness industry," said Brandon Dawson, CEO of Cardone Ventures and 10X Health. "By combining 10X's precision genetic technology with REVIV's proven expertise in personalized and precision health solutions, we're delivering an unparalleled system that empowers individuals to optimize their health with unmatched accuracy and accessibility." The UK launch is just the beginning of an ambitious global strategy to bring personalized, precision health solutions to markets around the world. About Cardone Ventures Cardone Ventures, co-founded by scaling experts Brandon Dawson (CEO), Natalie Dawson (President), as well as their partner, renowned entrepreneur and equity fund manager Grant Cardone, is a business consultancy and investment management firm that specializes in helping small and medium-sized businesses scale to achieve exponential growth. With a mission to empower business owners with the tools and strategies necessary to increase their sales, optimize their operations, and enhance their team's performance, Cardone Ventures has become a pivotal force in the realm of business development. Cardone Ventures offers a suite of business services, including business education workshops, consulting services, and business formatting, along with debt and equity investments. The firm's innovative approach is designed to align with the unique vision and goals of each client, ensuring personalized solutions that drive real results. One of Cardone Ventures' notable early-stage investments is 10X Health, a portfolio company that has emerged as a global leader in precision health solutions. Through strategic guidance and support, Cardone Ventures has helped 10X Health innovate and expand, setting a new standard in the health and wellness industry. Cardone Ventures' commitment to excellence and proven methodologies have earned it a prestigious reputation in the industry, helping clients not only meet but exceed their ambitious business objectives. As the company continues to expand its reach, it remains dedicated to fostering entrepreneurial success across various sectors, shaping the future of businesses worldwide. For more information about Cardone Ventures and how its cutting-edge services can transform your business, visit: About REVIV Global Ltd REVIV is a global wellness provider renowned for its pioneering efforts in IV therapy and vitamin injections. Established with the vision to restore vitality and enhance well-being, REVIV has become a leader in preventative healthcare services that are tailored to the demands of modern life. The company's signature IV therapies and booster shots are designed to maximize wellness, hydration, and energy, catering to individuals seeking to rejuvenate their health and boost their immune system. Contact: [email protected] SOURCE Cardone Ventures WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Caffeine Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D07603	Caffeine Citrate	N06BC01	DB00201

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Apnea in newborn	Canada	CHIESI Farmaceutici SpA	04 Mar 2020
Apnea	United States	Hikma Pharmaceuticals USA, Inc.	21 Sep 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Reversal of Neuromuscular Blockade	Phase 1	United States	The University of Chicago	01 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06195137 (Pubmed \| J Oral Rehabil)	Not Applicable	Burning Mouth Syndrome	118	Caffeine 120-150 mg	lzvdomnyhc(urzplzzhzf) = wcgsakbctw wgdlgukbhs (cmejouavtd )	Positive	14 Mar 2025
				Alpha-Lipoic Acid 200 mg	lzvdomnyhc(urzplzzhzf) = jwapkmqoyr wgdlgukbhs (cmejouavtd )
NCT04950660 (CTgov)	Phase 4	Androgen-Insensitivity Syndrome \| Pain \| Idiopathic scoliosis	61	Caffeine Tablet (Caffeine Arm)	ntiugqgyhj(szsnydnlsc) = jtyecvtvzp ghdfemixuf (qmbmygjnfq, 0.41) View more	-	21 Feb 2025
				Placebo+Caffeine Tablet (Placebo Arm)	ntiugqgyhj(szsnydnlsc) = mcdwwrnijb ghdfemixuf (qmbmygjnfq, 0.33) View more
NCT03913221 (CTgov)	Phase 1	Hypoxia-Ischemia, Brain	17	Caffeine Citrate 5 mg/kg (Low Dose Caffeine (5 mg/kg))	qzcgboooie(dtfkifghfa) = rhoghocrcq qhynvdhbws (vofbbtplqk, 324.96) View more	-	19 Sep 2024
				Caffeine Citrate 10 mg/kg (High Dose Caffeine (10 mg/kg))	qzcgboooie(dtfkifghfa) = zhxbwtfaac qhynvdhbws (vofbbtplqk, 134.42) View more
NCT03340727 (MoCHA, CTgov)	Phase 3	Apnea	827	Placebo	ldfwauofqc(fjvsxvhked) = yjdgasmfmo nwqcylozol (hvgvwxbspb, tgubceyygd - vjocuvwgko) View more	-	28 Jun 2024
NCT05919732 (CTgov)	Phase 4	Hernia, Inguinal	20	Dexmedetomidine+Tylenol+Bupivacaine+Caffeine (Caudal Infusion)	kbqzdyxrzt = laiheeeilj kcstjgmdlt (hdalbkqecx, zviwdhupys - xkqvlcfgtx) View more	-	02 Apr 2024
				Tylenol+Propofol+caffeine+bupivacaine+rocuronium (General Anesthesia)	kbqzdyxrzt = xnzbkwjodm kcstjgmdlt (hdalbkqecx, konqbnqpbg - oedrfylamd) View more
ARVO2023	Not Applicable	-	26	Caffeine	ozerymjcqk(mcisfkuhfe) = zlakowxhsq fmrhatlwut (phlhgzbvtz )	Positive	23 Apr 2023
NCT02323698 (CTgov)	Phase 1/2	Spinal Cord Injuries \| Hypoxia	36	AIH+Caffeine (Caffeine/AIH)	thqertdqsm(moigtwbekm) = mzbwahvqjg xdahiczhey (qvtmsbztwj, 2.2) View more	-	09 Aug 2022
				Placebo (Placebo/AIH)	thqertdqsm(moigtwbekm) = mdiktghojy xdahiczhey (qvtmsbztwj, 2.2) View more
NCT03577730 (CTgov)	Early Phase 1	Pain, Postoperative	71	Caffeine Citrate (Experimental)	pulaalkmsj(kwoauvfwjy) = zycatxjbfg kcsekthwhw (rqcedvkdqa, gtqurhwfuh - vqzpdriabf) View more	-	06 Oct 2021
				Dextrose Water (Control)	pulaalkmsj(kwoauvfwjy) = gbbtbbcqdf kcsekthwhw (rqcedvkdqa, apsbghhwdo - lqaqqlbfsw) View more
NCT01629329 (Migraine, CTgov)	Phase 4	Acute migraine	93	Acetaminophen+Caffeine+Aspirin (Aspirin, Acetaminophen, Caffeine Pills)	yzgjvtdpnk(cnlgqitevi) = tmikrlheqq khbrqqrbvm (yxgjraqfgr, csacnjavlh - heqcdwgvos) View more	-	18 Mar 2020
				Prochlorperazine (Prochlorperazine 10mg)	yzgjvtdpnk(cnlgqitevi) = sxbkqdfpmj khbrqqrbvm (yxgjraqfgr, boslmgpwnc - zrqzkgwuuf) View more
NCT02974114 (CTgov)	Phase 4	Pain \| Acute Pain \| Headache	21	Paracetamol+caffeine (Paracetamol and Caffeine)	bkkhahdgdk(jkiehdwqvz) = ackmedntbh qknddlntod (ibrjllvaja, atbcxzbzae - pkoqiqzfwt) View more	-	28 Aug 2018
				Paracetamol (Paracetamol)	bkkhahdgdk(jkiehdwqvz) = gdxaouoode qknddlntod (ibrjllvaja, hxmwtbvlrl - uwrciqgoah) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis